Sun Pharma Advanced Research Co (NSE:SPARC) Preferred Stock: ₹0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:SPARC Sun Pharma Advanced Research Co Ltd NSE:SPARC
49 GF Score
Price ₹235.20
GF Value ₹83.97
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Sun Pharma Advanced Research Co Preferred Stock?

Sun Pharma Advanced Research Co NSE:SPARC -6.09% 49 Preferred Stock is ₹0 Mil as of Mar. 2026. GuruFocus rates NSE:SPARC with a GF Score™ of 49/100 and a GF Value™ of ₹83.97 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Preferred stock is a special equity security that has properties of both equity and debt. Sun Pharma Advanced Research Co's preferred stock for the quarter that ended in Mar. 2026 was ₹0 Mil.

The market value of preferred stock needs to be added to the market value of common stocks in the calculation of Enterprise Value. Sun Pharma Advanced Research Co's Enterprise Value for the quarter that ended in Mar. 2026 was ₹42,849 Mil.

In the calculation of book value, the par value of preferred stocks needs to subtracted from total equity. Sun Pharma Advanced Research Co's Book Value per Share for the quarter that ended in Mar. 2026 was ₹41.26.

Dividends paid to preferred stocks need to be subtracted from net income in the calculation of Earnings per Share (Diluted). Sun Pharma Advanced Research Co's Earnings per Share (Diluted) for the three months ended in Mar. 2026 was ₹54.27.


Sun Pharma Advanced Research Co  (NSE:SPARC) Preferred Stock Explanation

When a company needs capital but does not wish to issue debt, they may sell preferred stocks to investors.

For instance, during the financial crisis of 2008, Goldman Sachs (GS) issued a combination of preferred stock and common stock options for $5 billion of capital to Warren Buffett’s Berkshire Hathaway (BRK.A)(BRK.B). In this deal, Berkshire Hathaway paid $5 billion for 10% cumulative perpetual preferred stock and warrants to buy 43.5 million shares of Goldman Sachs at $115 a share. Goldman Sachs bought back the preferred in 2010. Guess how much money Warren Buffett made in this deal in two years? Read How Much Did Warren Buffett’s Berkshire Hathaway (BRK.B) Make on Its Goldman Sachs (GS) Preferred Stock?

1. The market value of Preferred Stocks needs to be added to the market value of common stocks in the calculation of enterprise value.

Sun Pharma Advanced Research Co's Enterprise Value for the quarter that ended in Mar. 2026 is calculated as

2. In the calculation of Book Value, the par value of Preferred Stocks needs to subtracted from total equity.

Sun Pharma Advanced Research Co's Book Value per Share for the quarter that ended in Mar. 2026 is calculated as

3. Dividends paid to Preferred Stocks need to be subtracted from net income in the calculation of earnings per share.

Sun Pharma Advanced Research Co's Earnings per Share (Diluted) (EPS) for the three months ended in Mar. 2026 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sun Pharma Advanced Research Co Preferred Stock Related Terms


Sun Pharma Advanced Research Co Preferred Stock Historical Data

* Premium members only.

The historical data trend for Sun Pharma Advanced Research Co's Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sun Pharma Advanced Research Co Preferred Stock Chart

Sun Pharma Advanced Research Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Preferred Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Sun Pharma Advanced Research Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Preferred Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NSE:SPARC
49GF Score
Sun Pharma Advanced Research Co Ltd NSE:SPARC
Preferred Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sun Pharma Advanced Research Co Preferred Stock Calculation

Preferred Stock is a special equity security that has properties of both equity and debt. It is generally considered a hybrid instrument. Preferred stock is senior to common stock, but is subordinate to bonds in terms of claim or rights to their share of the assets of the company.

Preferred stock has priority over common stock in the payment of dividends and any payments received when a company liquidates.

Preferred stock comes in many forms. It can be:


Convertible or Non-Convertible
Cumulative or Non-Cumulative
Voting or Non-Voting
Callable or Non-Callable
Maturity Date or No Maturity Date

A preferred stock without a maturity date is called a perpetual preferred stock. These are relatively rare. A good example of perpetual preferred stock is the many series of Public Storage (PSA) preferred shares that trade on the New York Stock Exchange.

Before investing in preferred stock, it is important to know which of the above groups the stock belongs to. Is it convertible or non-convertible? Are dividends cumulative or non-cumulative?

It is also critical that an investor knows what bonds the company has in front of the preferred stock. Bondholders get paid first. So the decision to buy a preferred stock can be similar to the decision to buy a bond. But, remember, the preferred stock of a company with bonds is junior to those bonds.

Unless a preferred stock is convertible, the upside in a preferred stock investment is more limited than in a common stock investment. If a company doubles its earnings, it is usually under no more obligation to double the dividends paid to preferred shareholders than it is to double the interest paid to its bankers and bondholders.So preferred stock is very different from common stock.

Frequently Asked Questions Learn more about Preferred Stock →
What does a Preferred Stock of ₹0 Mil mean?
Sun Pharma Advanced Research Co (NSE:SPARC) has a Preferred Stock of ₹0 Mil as of Mar. 2026. Preferred Stock represents the par value of a company's preferred shares. View historical data on Sun Pharma Advanced Research Co and its competitors.
Is Sun Pharma Advanced Research Co's Preferred Stock too high?
Sun Pharma Advanced Research Co's current Preferred Stock is ₹0 Mil. Overall, Sun Pharma Advanced Research Co has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sun Pharma Advanced Research Co's Preferred Stock compare to ZTS and UTHR?
Sun Pharma Advanced Research Co's Preferred Stock of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Preferred Stock for a Drug Manufacturers company?
A good Preferred Stock depends on the Drug Manufacturers industry context. However, Preferred Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Preferred Stock mean?
A high Preferred Stock can signal that a stock is expensive relative to its fundamentals. Preferred Stock represents the par value of a company's preferred shares. View historical data on Sun Pharma Advanced Research Co and its competitors. Sun Pharma Advanced Research Co's current Preferred Stock is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sun Pharma Advanced Research Co stock overvalued right now?
Based on GuruFocus' analysis, Sun Pharma Advanced Research Co (NSE:SPARC) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹83.97, compared to a current price of ₹235.20 — trading 180.1% above its estimated fair value. The current Preferred Stock is ₹0 Mil. Sun Pharma Advanced Research Co's overall GF Score™ is 49/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Preferred Stock calculated?
Preferred Stock is calculated from a company's financial statements. For Sun Pharma Advanced Research Co (NSE:SPARC), the current Preferred Stock is ₹0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sun Pharma Advanced Research Co (NSE:SPARC) Overvalued in 2026?

Based on GuruFocus' analysis, Sun Pharma Advanced Research Co stock appears to be overvalued. The current stock price of ₹235.20 is trading 180.1% above its estimated GF Value™ of ₹83.97. GuruFocus considers Sun Pharma Advanced Research Co to be Significantly Overvalued.

Key valuation signals for NSE:SPARC:

  • Preferred Stock: ₹0 Mil
  • GF Value™: ₹83.97 vs. price of ₹235.20 (180.1% above fair value)
  • GF Score™: 49/100 with 5 warning signs

No single metric tells the full story. See the NSE:SPARC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sun Pharma Advanced Research Co Business Description

Other Exchanges 532872:India
Address Off Mahakali Caves Road, 17-B, Mahal Industrial Estate, Andheri (East), Mumbai, MH, IND, 400093
Sun Pharma Advanced Research Co Ltd is an Indian specialty and generic drug manufacturing company. The company has identified pharmaceuticals research and development as its only reportable segment. The company is focused on drug discovery in focused therapy areas such as cancer and anti-inflammatory treatments. The company considers merger and acquisition investment as a potential component of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities. It derives maximum revenue from India and also has its presence in other countries.
49GF Score

Get the complete analysis for NSE:SPARC

Preferred Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹235.20
Price
₹83.97
GF Value